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Abstract
Background Given that the quinolones is one of the
antibacterial classes most frequently used to treat patients
with bacterial infections in the United States, any change in
prescribing patterns of quinolones will impact Medicaid
medical expenditures.
Objectives This study was undertaken to examine trends in
utilization, reimbursement, and prices of quinolone
antibacterials for the US Medicaid population.
Methods The publicly available Medicaid State Drug
Utilization outpatient pharmacy files were used for this
study. Quarterly and annual prescription counts and reim-
bursement amounts were calculated for each of the qui-
nolones reimbursed by Medicaid from quarter 1, 1991
through quarter 2, 2015. Average per-prescription reim-
bursement, as a proxy for drug price, was calculated as the
drug reimbursement divided by the number of
prescriptions.
Results The total annual number of quinolone prescrip-
tions increased 402%, from 247,395 in the first quarter of
1991 to 1.2 million in the second quarter of 2015, peaking
at 1.3 million in the first quarter of 2005. Similarly, the
total reimbursement for quinolone agents increased by
245.5% over the same period. More than 80% of quinolone
prescriptions reimbursed by Medicaid were for the second-
generation agent, ciprofloxacin, and the third-generation
agent, levofloxacin. The average payment per prescription
for quinolones increased from US$43.8 in the first quarter
of 1991 to US$87.6 in the second quarter of 2015.
Conclusions A substantial rise in Medicaid expenditures
on quinolones was observed during the 25-year study
period, which was mainly because of rising utilization.
Therefore, there is a need for additional research that has
access to clinically relevant data with which to measure the
rate of inappropriate quinolone use among the Medicaid
population and associated clinical outcomes and healthcare
costs.
Key Points for Decision Makers
The total annual number of US Medicaid-reimbursed
prescriptions for quinolones (branded and generic)
increased 402%.
More than 80% of quinolone prescriptions
reimbursed by Medicaid were for ciprofloxacin and
levofloxacin.
From 1991 to 2015, Medicaid spending on quinolone
medications rose by 245.5%, from US$11.8 million
to US$40.8 million.
The average payment per prescription for quinolones
increased from US$43.8 in the first quarter of 1991
to US$87.6 in the second quarter of 2015.
Electronic supplementary material The online version of this
article (doi:10.1007/s41669-016-0007-y) contains supplementary
material, which is available to authorized users.
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Medical practice in the United States has changed dra-
matically over the last several decades, and one of those
changes has been an increase in the use of antibacterial
drugs [1]. As publicly funded healthcare systems like
Medicaid face shrinking resources and concomitant deci-
sions about the allocation of finite resources, searching for
ways to improve quality and decrease costs of treatment of
infectious diseases will become particularly important.
Forty-eight percent to 59% of outpatient visits by the
Medicaid-enrolled population annually were linked with a
filled antibiotic prescription [2]. One of the antibacterial
classes most frequently used to treat patients with bacterial
infections in the US is quinolones. Thus, any change in
prescribing patterns of quinolones will impact the Medi-
caid medical expenditures [3].
The prolific development of the quinolones as a class of
antibacterials dates back to the discovery of nalidixic acid
(NegGram) in 1962. This was followed by the introduction
of the first quinolone, norfloxacin, then ciprofloxacin
(Cipro, Bayer Healthcare Division) in the mid-1980s, both
of which have an extended spectrum of activity and
improved pharmacokinetics compared with nalidixic acid
[4, 5]. According to IMS Health, and with the introduction
of other quinolone agents, the utilization of quinolones
increased to make this novel class of antibacterial medi-
cations the most commonly prescribed class of antibiotics
in the US in 2009 [6].
Because of the above-mentioned improved pharma-
cokinetic and pharmacodynamic properties of quinolones
and their activity against a wide range of multi-resistant
pathogens [7–11], these compounds have now been used
widely in clinical practice. They are used for the treatment
of several bacterial infections, including genitourinary tract
infections, respiratory infections, skin infections, joint or
bone infections, intra-abdominal infections, and ocular
infections (Appendix Table A-1, see electronic supple-
mentary material) [12].
Assessing more recent healthcare providers’ patterns of
prescribing quinolones and their cost variability is impor-
tant for several reasons. First, from previous experience
with other antibacterials, medical providers know that the
increased use of these agents could lead to increased
resistance, a worldwide concern in the medical community
[13]. Infections caused by resistant bacteria are associated
with increased risk of worse clinical outcomes and death,
and patients with antibiotic-resistant bacterial infections
consume more healthcare resources than patients infected
with the same bacteria who are not resistant [14]. It was
estimated that treating infections caused by resistant bac-
teria costs North America US$5 billion dollars every year
[15]. Second, the cost of these agents also has an economic
impact on the patients and, most importantly, payers in
healthcare systems.
There are a few studies that have examined the overall use
of quinolone antibacterials; however, they focused only on
specific infectious conditions [16, 17]. Therefore, we sought
to examine trends in utilization, reimbursement, and prices
of quinolone antibacterials for the US Medicaid population
over the 25 years from 1991 through 2015. By doing so, this
study may help healthcare providers and payers, such as
Medicaid, to be able to establish strategies directed at opti-
mizing the use of quinolones and limiting the development of
resistance to these important medicines.
2 Methods
2.1 Study Population and Data Source
Medicaid is the nation’s main public financing program
covered healthcare services for low-income Americans.
From 1991 to 2015, the number of Medicaid enrollees
increased from 32.2 to 68.9.7 million; they account for
approximately 20% of the US population. African Ameri-
cans account for about 22% and White Americans for 41%,
females for[58%, and those B17 years for about 48% of
the population in Medicaid. Despite the rapid growth of the
number of Medicaid program beneficiaries, these propor-
tions of total Medicaid enrollment held steady over the last
several decades [18–21].
This study was designed as a retrospective drug uti-
lization study that examined the period of 1991–2015 using
data from the national Medicaid pharmacy files provided
by the Centers for Medicare & Medicaid Services (CMS).
These files contain information about numbers of pre-
scriptions and total Medicaid payments to pharmacies for
individual drug products. The CMS collects these data
from the states for use in the federal Medicaid drug rebate
program, and they are updated on a quarterly basis.
We extracted utilization and expenditure data for all
quinolone drug forms in the database by each of 49 states
(all states except Arizona) plus the District of Columbia
[22]. It should be noted that this database contains some
reporting errors, specifically in 2006. If data for a particular
medication for a specific quarter were considered erratic,
the average of values from previous and/or later quarters
was used to estimate the data.
2.2 Measures
Total quinolone prescriptions and total reimbursement
costs (i.e., total pharmacy reimbursement amount,
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including drug cost and dispensation fee, not separated)
were calculated by adding the data for all years for each
quinolone. Prescription drug records included all qui-
nolone medications dispensed within the study period,
including those that have been withdrawn from the
market. We searched the database using both trade
name and generic name for every quinolone. Table 1
lists the quinolone drugs covered by Medicaid, as well
as the manufacturers, approval dates, and patent expi-
ration dates for all quinolones [23]. Because the price
per prescription is not accessible in the data, we cal-
culated per-prescription reimbursement (also referred to
loosely as ‘price’ throughout this paper) as total
expenditure for the drug divided by the total number of
prescriptions. This price is prerebate which didn’t
account for rebates or discounts supplemented by
negotiations with drug manufacturers. Although per-
prescription reimbursement measure may be not ideal,
this conservative estimation approach of price has been
widely used by researchers studying the Medicaid pro-
gram and its expenses using the same data source,
including Jing et al. [24], Chen et al. [25], Bian et al.
[26], Chiu et al. [27], Desai et al. [28], and Gorevski
et al. [29].
All expenditure values are expressed in US dollars.
All analyses were performed using both SAS Version 9.4
(SAS Institute Inc., Cary, NC, USA) and Microsoft
Excel 2007 (Microsoft Corporation, Redmond, WA,
USA).
3 Results
Figure 1 shows the quarterly quinolone drug utilization by
Medicaid beneficiaries. Across the 49 programs in our
sample, the total annual number of Medicaid-reimbursed
prescriptions for quinolones (branded and generic)
increased 402%, from 247,395 in the first quarter of 1991
to 1.2 million in the second quarter of 2015, peaking at
1.3 million in the first quarter of 2005.
On closer examination of the data, the majority of the
decrease in quinolone prescriptions occurred after the first
quarter of 2006. Levofloxacin had the most rapidly rising
utilization rate among all quinolones after it was introduced
to the market at the end of 1996, reaching a peak in 2004
with a 1647.1% increase in its 1997 utilization rate.
However, it was not long until the number of levofloxacin
prescriptions started to drop steadily to reach 85.1% of the
2004 figure in 2010, two quarters before generic versions
of levofloxacin entered the US market.
The second-generation agent, ciprofloxacin, and the
third-generation agent, levofloxacin clearly dominated the
market through most of the study period. More than 80% of
quinolone prescriptions reimbursed by Medicaid were for
those two drugs. During the study period, 44.5 million
prescriptions for ciprofloxacin and 19.7 million prescrip-
tions for levofloxacin were received by Medicaid benefi-
ciaries. Ofloxacin was the next most commonly prescribed
quinolone (11.3%) (Appendix Table A-2, see electronic
supplementary material). The total number of prescriptions
Table 1 Quinolones purchased by the US Medicaid program from 1991 to 2015
Therapeutic class Brand name Generic name FDA approval date Manufacturer Patent expiration
First generation NegGram Nalidixic acid 1967 Winthrop Laboratories NA
Cinobac Cinoxacin 13 Jun 1980 Eli Lilly NA
Second generation Noroxin Norfloxacin 31 Oct 1986 Merck NA
Cipro Ciprofloxacin 22 Oct 1987 Bayer HealthCare 26 Sep 2003
Floxin Ofloxacin 28 Dec 1990 Janssen Pharmaceuticals 16 Jan 2002
Penetrex Enoxacin 31 Dec 1991 Sanofi Aventis US NA
Maxaquin Lomefloxacin 21 Feb 1992 Pharmacia NA
Third generation Omniflox Temafloxacin 31 Jan 1992 Abbott Laboratories NA
Levaquin Levofloxacin 20 Dec 1996 Janssen Pharmaceuticals 20 Jun 2011
Zagam Sparfloxacin 19 Dec 1996 Mylan NA
Avelox Moxifloxacin 10 Dec 1999 Bayer AG 27 Jun 2012
Zymar Gatifloxacin 28 Mar 2003 Allergan 19 Aug 2011
Fourth generation Trovan Trovafloxacin 18 Dec 1997 Pfizer NA
Factive Gemifloxacin 4 Apr 2003 LG Life Sciences 4 Apr 2017
Besivance Besifloxacin 28 May 2009 Bausch and Lomb NA
Source: Food and Drug Administration [12]
NA not applicable
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for ofloxacin increased from 2125 in the first quarter of
1991–223,315 by the end of study period. Norfloxacin was
the first approved quinolone for use in the US in 1986;
however, it now has limited indications and is infrequently
used. The number of reimbursed norfloxacin prescriptions
decreased from 293,615 in 1991 to only four prescriptions
during the first and the second quarters of 2015. The most
recently approved quinolones (gemifloxacin and gati-
floxacin), except the newest entrant, besifloxacin, have
experienced a drop in number of prescriptions over most of
their time in the market.
The total number of prescriptions of nalidixic acid, the
first of the synthetic quinolone antibacterials, is only
51,327 during the study period. Because of the availability
of less toxic, more effective, and less frequent dosing
agents in the US, the last nalidixic acid prescribed for a
Medicaid beneficiary was in 2007. Finally, the following
agents: cinoxacin, enoxacin, lomefloxacin, sparfloxacin,
temafloxacin, and trovafloxacin, were either discontinued
or withdrawn from the market after various periods of time
due to the severe adverse reactions experienced by patients
[30]. Therefore, the utilization of these drugs was very
limited during the time they were available.
The total payment for quinolone agents increased by
245.5% during the second quarter of 2015 compared with
the first quarter of 1991. Similar to utilization, the Medi-
caid spending trend for quinolones was dominated by
ciprofloxacin and levofloxacin (Fig. 2). Between 1991 and
2013, Medicaid spent 46.9% of total spending on quino-
lones on ciprofloxacin and 29.8% on levofloxacin. Moxi-
floxacin came in third at 11.9%, and ofloxacin was fourth at
7.8% of spending (Appendix Table A-3, see electronic
supplementary material).
Bayer enjoyed patent protection for its highly successful
antibacterial ciprofloxacin (Cipro) until the end of 2003.
When the first generic ciprofloxacin (for Cipro) became
available in 2004, the spending on ciprofloxacin decreased
from US$41.2 million in the third quarter of 2004 to
US$16.9 million in the first quarter of 2005. Similarly,
after the first generic copy of Levaquin was launched, the
spending on levofloxacin decreased from US$16.2 million
in the second quarter of 2011 to US$2.6 million in the third
quarter of 2012.
Overall payment per prescription increased between
1991, quarter 1 and 2015, quarter 2 (Fig. 3). Several qui-
nolones had large price changes as well during the second
half of the study period. The average payment per pre-
scription for quinolones increased 100% during the study
period. The price of ciprofloxacin has decreased 20.2%,
and the prices for levofloxacin and ofloxacin have behaved
similarly to those of ciprofloxacin (Appendix Table A-4,
see electronic supplementary material). Since 1997 quarter
1, levofloxacin had a gradual price increase, followed by an
abrupt price decrease from US$172 per prescription in the
second quarter of 2011 to US$28.6 per prescription in the
second quarter of 2012 (83.3% decrease). As was observed,
ofloxacin gradually increased in price from an average of
US$51 per prescription in the first quarter of 1991 to
US$78.2 per prescription in the fourth quarter of 2007,
followed by a gradual price decrease until it reached
US$23.7 per prescription at the end of the study period.
Norfloxacin has shown a price increase over time since
1991. Whereas the prices of all quinolones slowly
increased or decreased from 1991 to 2015, the price of
trovafloxacin climbed abruptly within 1 year from
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Fig. 1 Utilization of
quinolones by quarter in
Medicaid from 1991 to 2015
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US$253.6 per prescription in the same quarter of 2003,
before it was withdrawn from the market in 2004 due to the
risk of hepatotoxicity [30].
4 Discussion
A retrospective descriptive study of quinolone antibacterial
utilization, expenditures, and average prices from 1991
through 2015 was conducted using reliable data about
antibacterial utilization in the large US pharmaceutical
market. A substantial rise in Medicaid expenses on qui-
nolones was observed during the 25-year study period,
which was mainly because of increasing utilization.
The highest demand is observed for ciprofloxacin and
levofloxacin, which represent 80% of all quinolone pre-
scriptions. That is not surprising because ciprofloxacin and
levofloxacin are valued for their broad spectrum of activity
and availability in both oral and intravenous forms in
addition to their lower cost. Moreover, nearly all state
Medicaid programs cover ciprofloxacin and levofloxacin as
preferred drugs. Drugs designated as preferred have been
selected by the Drug Utilization Review (DUR) Board for
their efficaciousness, cost effectiveness and safety for
Medicaid beneficiaries to encourage the use of less
expensive drugs equal in efficacy to more expensive
alternatives within a therapeutic class [31]. Other quino-
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submitted by the prescriber. One of the potential explana-
tions for why utilization of some quinolone prescriptions,
such as gatifloxacin, gemifloxacin, and norfloxacin, has
decreased over time is because of an increase in the
reported adverse effects of these medications [30].
In 2006, the overall quinolone utilization and total
payments to pharmacies dropped significantly after the
implementation of Medicare Part D, also called the
Medicare prescription drug benefit, for dual-eligible ben-
eficiaries (i.e., beneficiaries enrolled in both Medicare and
Medicaid). These dual-eligibles (i.e., over 6 million bene-
ficiaries) accounted for about half of Medicaid’s total
expenses on prescription drugs before 2006 [32, 33]. This
resulted in a major shift of prescription drug spending from
Medicaid to Medicare.
Our findings show a substantial increase in the total cost
of quinolones over the study period across all the medi-
cations studied. The increase in quinolone costs is partially
attributable to the introduction of a number of branded
expensive products such as gemifloxacin and besifloxacin,
in addition to moxifloxicin (generic), which was approved
by the FDA on February 18, 2014. This increase in per-
prescription costs might also be driven by an increase in
underlying costs such as the dispensing fee that is incurred
by pharmacies.
However, it is known that the antimicrobial market is
highly competitive, both within and between chemical
classes. In our analysis, ciprofloxacin, levofloxacin, and
ofloxacin were the quinolones most often prescribed by
doctors for Medicaid beneficiaries. Once a brand-name
drug’s patent expires, generic versions of the drug quickly
become available. The market competition often leads to
substantially lower prices as was observed in quarter 4 of
2003 for ciprofloxacin and in the second quarter of 2011
for levofloxacin. On the other hand, the availability of the
generic equivalents of Floxin in the market had no impact
on the expenditure on this medication for Medicaid. This is
because Floxin was not a very profitable drug [34].
Because some of the medications in this class have been
recently approved by the FDA, such as gemifloxacin and
besifloxacin, Medicaid programs will not take advantage of
the availability of generic versions of these medications
before their patent expiration dates. Until then, Medicaid
expenditures on branded quinolones are expected to con-
tinue to grow for a number of years. For this reason, the
cost effectiveness of quinolone prescribing must be bal-
anced with quality of care.
What these data cannot tell us is how much of a given
rate of these antibacterial uses reflects overuse, underuse,
and appropriate use. However, evidence is mounting that
suggests the inappropriate use rate of quinolones increased
over the past years when quinolones were prescribed for
non-infectious or non-bacterial syndromes [35–38].
In response to growing concern for antibacterial resis-
tance, many organizations have launched initiatives to
improve antibacterial use, such as the Centers for Disease
Control and Prevention (CDC). The CDC launched the Get
Smart for Healthcare initiative [39] in 2004, which includes
a national campaign to promote educating providers and
the public, as well as key partners, such as policy makers
and state and local public health officials, about the
importance of preserving the effectiveness of antibiotics.
Although the initial success of these efforts on antibiotic
use has been previously reported [40–44], our results
suggest that these improvements appear to have been short-
lived and that the greatest impact of this policy occurred
shortly after its introduction and during the next few years.
Unfortunately, quinolone antibacterial utilization rates
have increased steadily since 2010—to reach their highest
level by the end of the study period. Although our results
do not prove that the campaign, in fact, caused a reduction
in quinolone prescriptions, it may be a promising way to
reduce the overuse of quinolones and to slow the spread of
antibacterial resistance. Thus, further research to identify
the effect of the campaign on antibacterial use by relating
differential changes in quinolone use over time to changes
in the relevant policy variables is warranted. The results of
this research would allow for more focused interventions or
policy changes on improving the use of quinolones.
The reasons why physicians continue to overuse
antibiotics such as quinolones are complex; however, two
documented potential explanations exist for this issue.
First, many prescribers intend to use a broader-spectrum
agent than necessary to ensure the patient will return next
time they are ill if the infection is treated adequately [45].
Second, patients expect to be prescribed medication at the
end of the visit [46]. This expectation led some prescribers
to increase their antibacterial-prescribing habit to ensure
the patients were satisfied with their care. According to
findings from a recent observational study, which was
conducted to examine the necessity of administered oral
and parenteral quinolones, 31% of antibacterials prescribed
are unnecessary [47]. Therefore, rational prescribing of
these drugs can minimize costs and give the best outcome
in terms of both clinical care and reducing the risk of
widespread quinolone resistance [48–55].
The main strengths of this study are the long study
period and the large representative study group. However,
these results should be considered in light of the limitations
of this study. First, because patient-specific information
was not available in the database, the appropriateness of
the quinolone medication use was not assessed. Second,
payment per prescription may be an imperfect measure of
prescription price, because it was not adjusted for strengths
or dosage forms due to the lack of detailed prescription
data. However, there is no explicit reason to suspect that
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the results of the study are skewed because we aimed to
explore the trends over time when the utilization differ-
ences between the strengths and dosage forms for each
drug may be relatively consistent over time. Third, actual
acquisition costs cannot be measured and our costs may be
overestimated because estimating the cost of a therapy
course of a particular quinolone has many difficulties, such
as manufacturer rebates [i.e., 15.1% of the average manu-
facturer price (AMP) or the difference between the AMP
and the lowest price set to any buyer in the US] and
agreements between health systems and pharmacies that
affect acquisition cost [56]. Fourth, it is noteworthy that
beneficiaries in Medicaid managed-care plans may receive
prescriptions not reflected in Medicaid pharmacy files.
However, a previous study has suggested that the potential
for incomplete data is minimal [57]. Fifth, our study is
based on the combined data of all state Medicaid programs
and drug prices can differ considerably across government
programs [56]. However, our results should be of interest to
state policy makers because they can compare the results of
their costs with those of all regions. Sixth, in May 2016, the
FDA encouraged medical providers to avoid prescription of
quinolones for respiratory tract infections and urinary tract
infections unless alternatives have been tried and were
unsuccessful. This restriction on quinolones could have an
impact on the utilization of this class which couldn’t be
captured in the study period [58]. Finally, the external
validity of our findings is limited because our results were
derived from a Medicaid population that heavily comprises
women and children. However, our findings have impor-
tance for decision makers, since these data can be used as a
baseline measure of the use and costs associated with
quinolone prescribing in a US healthcare setting.
5 Conclusion
Quinolones are among the most commonly prescribed
antibacterials for US Medicaid enrollees. Analysis of the
Medicaid database revealed an increase in prescriptions
written for quinolone drugs between 1991 and 2015.
However, because this increase in the use of quinolones in
recent years has coincided with steady increases in the
incidence of quinolone resistance, there is a need for
additional research that has access to clinically relevant
data with which to measure the rate of inappropriate qui-
nolone use among the Medicaid population and associated
clinical outcomes and healthcare costs. The finding of these
studies would not only help to control drug expenditures,
but also minimize the potential health hazards from
unnecessary antibacterial use. Furthermore, the assessment
of the impact of the conducted campaign on levels of
antibacterial consumption is necessary to point to targets
where antibacterial stewardship programs and corrective
policies can be implemented to optimize quinolone
antibacterial use.
Compliance with Ethical Standards
Data availability statement The datasets analyzed during the cur-
rent study are publicly available from Centers for Medicare &
Medicaid Services at https://www.medicaid.gov/medicaid/
prescription-drugs/state-drug-utilization-data/index.html.
Funding This research did not receive any specific grant from
funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of interest The authors Ziyad S. Almalki, Xiaomeng Yue,
Ying Xia, Patricia R. Wigle, and Jeff Jianfei Guo have indicated that
they have no conflicts of interest with regard to the content of this
article.
Author contributions ZSA carried out the literature review, statis-
tical analyses, manuscript drafting, manuscript editing, and manu-
script revision. XY carried out the study design, statistical analyses,
and manuscript revision. YX participated in data collection, statistical
analyses, and manuscript editing. PRW participated in manuscript
editing and manuscript revision. JJG participated in study design and
data collection, manuscript editing, manuscript revision, and coordi-
nation. All authors read and approved the final manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Lichtenberg FR. Are the benefits of newer drugs worth their cost?
Evidence from the 1996 MEPS. Health Aff. 2001;20(5):241–51.
2. Nett RJ, et al. Office-related antibiotic prescribing for Medicaid-
enrolled children. Clin Pediatr: 0009922813479158 (2013).
3. Berman S, et al. Otitis media-related antibiotic prescribing pat-
terns, outcomes, and expenditures in a pediatric Medicaid pop-
ulation. Pediatrics.1997;100.4: 585–592.
4. Linder JA, et al. Fluoroquinolone prescribing in the United
States: 1995 to 2002. Am J Med. 2005;118(3):259–68.
5. Lesher GY, et al. 1, 8-Naphthyridine derivatives. A new class of
chemotherapeutic agents. J Med Chem. 1962;5(5):1063–5.
6. Suda KJ, et al. A national evaluation of antibiotic expenditures by
healthcare setting in the United States, 2009. J Antimicrob
Chemother. 2012: dks445.
7. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoro-
quinolones. Drugs. 1999;58(Suppl 2):29–36.
8. Hane MW, Wood TH. Escherichia coli K-12 mutants resistant to
nalidixic acid: genetic mapping and dominance studies. J Bacte-
riol. 1969;99:238–41.
9. Yoshida H, Kojima T, Yamagishi J, Nakamura S. Quinolone-
resistant mutations of the gyrA gene of Escherichia coli. Mol Gen
Genet. 1988;211:1–7.
10. Nakamura S, Nakamura M, Kojima T, Yoshida H. gyrA and gyrB
mutations in quinolone-resistant strains of Escherichia coli.
Antimicrob Agents Chemother. 1989;33:254–5.
Quinolone Antibacterials in the US Medicaid Program
11. Phillips I, King A, Shannon K. Comparative in vitro properties of
the quinolones. In: Andriole VT, editor. the quinolones. 3rd ed.
San Diego: Academic Press; 2000. p. 99–137.
12. Drugs@FDA. [Mar. 15, 2015]. Available at: http://www.
accessdata.fda.gov.proxy.libraries.uc.edu/Scripts/cder/Drugsat
FDA/index.cfm. Accessed 15 Mar 2016.
13. Holmberg SD, Solomon SL, Blake PA. Health and economic
impacts of antimicrobial resistance. Rev Infect Dis.
1987;9(6):1065–78.
14. Linden PK. Clinical implications of nosocomial gram-positive
bacteremia and superimposed antimicrobial resistance. Am J
Med. 1998;104(5):24S–33S.
15. Goff DA. Antimicrobial stewardship: bridging the gap between
quality care and cost. Curr Opin Infect Dis. 2011;24:S11–20.
16. Barnett ML, Linder JA. Antibiotic prescribing for adults with
acute bronchitis in the United States, 1996–2010. JAMA.
2014;311(19):2020–2.
17. Lee GC, et al. Outpatient antibiotic prescribing in the United
States: 2000 to 2010. BMC Med. 2014;12(1):1.
18. Patrick SW, Freed GL. Intergenerational enrollment and expen-
diture changes in Medicaid: trends from 1991 to 2005. BMC
Health Serv Res. 2012;12(1):1.
19. Kaiser Family Foundation. http://kff.org/other/state-indicator/
total-population. Accessed 15 June 2016.
20. Kaiser Family Foundation. http://kff.org/medicaid/issue-brief/
medicaid-update-expenditures-and-beneficiaries-in-1994/. Acces-
sed 15 June 2016.
21. Centers for Medicare &Medicaid Services. https://www.cms.gov/
research-statistics-data-and-systems/statistics-trends-and-reports/
nationalhealthexpenddata/nhe-fact-sheet.html. Accessed 15 June
2016.
22. Centers for Medicare & Medicaid Services. State Drug Utilization
https://www.medicaid.gov/medicaid-chip-program-information/by-
topics/benefits/prescription-drugs/medicaid-drug-rebate-program-
data.html. Accessed 9 Mar 2016.
23. Food and Drug Administration: [http://www.accessdata.fda.gov/
scripts/cder/drugsatfda/]. Accessed 14 Mar 2016.
24. Jing Y, et al. Utilization and spending trends for antiretroviral
medications in the US Medicaid program from 1991 to 2005.
AIDS Res Therapy. 2007;4(1):1.
25. Chen Y, et al. Utilization, price, and spending trends for
antidepressants in the US Medicaid Program. Res Soc Adm
Pharm. 2008;4(3):244–57.
26. Bian B, et al. ACE Inhibitor and ARB utilization and expendi-
tures in the Medicaid fee-for-service program from 1991 to 2008.
J Manage Care Pharm. 2010;16(9):671–9.
27. Chiu S-F, et al. Utilization, spending, and price trends for short-
and long-acting Beta-agonists and inhaled corticosteroids in the
medicaid program, 1991–2010. Am Health Drug Benefits.2011;
4.3.
28. Desai VC, et al. Trends in the utilization of, spending on, and
prices for outpatient antifungal agents in US Medicaid programs:
1991–2009. Clin Ther. 2012;34(10):2118–31.
29. Gorevski E, et al. Utilization, spending, and price trends for
benzodiazepines in the US Medicaid program: 1991–2009. Ann
Pharmacother. 2012;46(4):503–12.
30. Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin:
the next generation of fluoroquinolones? Am J Health-Syst
Pharm. 1997;54(22):2569–84.
31. Patient safety forum: Do state medicaid preferred drug lists affect
patient safety? (2005). Psychiatric Services, 56(8), 1012.
Retrieved from http://search.proquest.com/docview/213063845?
accountid=2909.
32. Kaiser Family Foundation: http://kff.org/medicaid/report/the-
transition-of-dual-eligibles-to-medicare/. Accessed 14 Mar 2016.
33. Bruen BK, Miller LM. Changes in Medicaid prescription volume
and use in the wake of Medicare Part D implementation. Health
Aff. 2008;27(1):196–202.
34. ‘‘OFLOXACIN.’’ New Drug Approvals. Available at: https://
newdrugapprovals.org/2015/03/12/ofloxacin/. Accessed 1 June
2016.
35. Owens RC, Ambrose PG. Antimicrobial safety: focus on fluo-
roquinolones. Clin Infect Dis. 2005;41(Suppl. 2):S144–57.
36. Dydek GJ, Souney PF, Matthews SJ. DUE of ciprofloxacin in the
treatment of urinary tract infections in hospitalized patients. Hosp
Formul. 1992;27(2):185–91.
37. Lautenbach E, et al. Fluoroquinolone utilization in the emergency
departments of academic medical centers: prevalence of, and risk
factors for, inappropriate use. Arch Intern Med.
2003;163(5):601–5.
38. Almalki ZS, Alahmari AK, Guo JJ, Cavanaugh TM. Off-label use
of oral fluoroquinolone antibiotics in outpatient settings in the
United States, 2006 to 2012. Pharmacoepidemiol Drug Saf.
2016;25:1042–251.
39. Centers for Disease Control and Prevention. Get Smart: Know
When Antibiotics Work. Get Smart Web site. http://www.cdc.
gov/getsmart/. Accessed 23 Mar 2016.
40. Belongia EA, Sullivan BJ, Chyou PH, Madagame E, Reed KD,
Schwartz B. A community intervention trial to promote judicious
antibiotic use and reduce penicillin-resistant Streptococcus
pneumoniae carriage in children. Pediatrics. 2001;108:575–83.
41. Perz JF, Craig AS, Coffey CS, et al. Changes in antibiotic pre-
scribing for children after a community-wide campaign. JAMA.
2002;287:3103–9.
42. Hennessy TW, Petersen KM, Bruden D, et al. Changes in
antibiotic-prescribing practices and carriage of penicillin-resistant
Streptococcus pneumoniae: a controlled intervention trial in rural
Alaska. Clin Infect Dis. 2002;34:1543–50.
43. Gonzales R, Corbett KK, Wong S, et al. ‘‘Get smart Colorado’’:
impact of a mass media campaign to improve community
antibiotic use. Med Care. 2008;46:597–605.
44. Finkelstein JA, Huang SS, Kleinman K, et al. Impact of a16-
community trial to promote judicious antibiotic use in Mas-
sachusetts. Pediatrics. 2008;121:e15–23.
45. Bauchner H, Pelton SI, Klein JO. Parents, physicians, and
antibiotic use. Pediatrics. 1999;103(2):395–401.
46. Little PS, Williamson I. Are antibiotics appropriate for sore
throats? costs outweigh the benfits. BMJ. 1994;309:1010–1.
47. Werner NL, et al. Unnecessary use of fluoroquinolone antibiotics
in hospitalized patients. BMC Infect Dis. 2011;11(1):1.
48. Carmeli Y, et al. Emergence of antibiotic-resistant Pseudomonas
aeruginosa: comparison of risks associated with different
antipseudomonal agents. Antimicrob Agents Chemother.
1999;43(6):1379–82.
49. Dziekan G, et al. Methicillin-resistant Staphylococcus aureus in a
teaching hospital: investigation of nosocomial transmission using
a matched case-control study. J Hosp Infect. 2000;46(4):263–70.
50. El Amari EB, et al. Influence of previous exposure to antibiotic
therapy on the susceptibility pattern of Pseudomonas aeruginosa
bacteremic isolates. Clin Infect Dis. 2001;33(11):1859–64.
51. Graffunder EM, Venezia RA. Risk factors associated with
nosocomial methicillin-resistant Staphylococcus aureus (MRSA)
infection including previous use of antimicrobials. J Antimicrob
Chemother. 2002;49(6):999–1005.
52. Weber SG, et al. Fluoroquinolones and the risk for methicillin-
resistant Staphylococcus aureus in hospitalized patients. Emerg
Infect Dis. 2003;9(11):1415–22.
53. Crowcroft NS, et al. Methicillin-resistant Staphylococcus aureus
and antimicrobial use in Belgian hospitals. Infect Control Hosp
Epidemiol. 1999;20(01):31–6.
Z. S. Almalki et al.
54. Bhavnani SM, et al. Effect of fluoroquinolone expenditures on
susceptibility of Pseudomonas aeruginosa to ciprofloxacin in US
hospitals. Am J Health-Syst Pharm. 2003;60(19):1962–70.
55. Zervos MJ, et al. Relationship between fluoroquinolone use and
changes in susceptibility to fluoroquinolones of selected patho-
gens in 10 United States teaching hospitals, 1991–2000. Clin
Infect Dis. 2003;37.12:1643–1648.
56. Duggan M, Scott Morton F. The distortionary effects of gov-
ernment procurement: evidence from Medicaid prescription drug
purchasing. No. w10930. National Bureau of Economic
Research, 2004.
57. Kelton CML, et al. Firm-and drug-specific patterns of generic
drug payments by US Medicaid programs: 1991–2008. Appl
Health Econ Health Policy. 2014;12(2):165–77.
58. Auwaerter P, Medscape. ‘‘Fluoroquinolones Not First Line: FDA
Advisory Reinforces Standard Practice in Ambulatory Care.’’
(http://www.medscape.com/viewarticle/863778). Retrieved 2
June 2016.
Quinolone Antibacterials in the US Medicaid Program
